A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB

• Status: Recruiting
• Trial end date: 2027-08-03
• Target enrollment: 0
• Participant gender: All

Summary

A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
• Collaborators: Huashan Hospital; No.85 Hospital, Changning, Shanghai, China; Shanghai Public Health Clinical Center
• Treatments: Interleukin-2; Zoledronic Acid

Criteria

Inclusion Criteria:

• RR-TB/MDR-TB (resistant to at least isoniazid and rifampicin).

• Poor efficacy of the original treatment regimen or no response to treatment or less than 4 effective drugs.

Exclusion Criteria:

• Immunosuppression due to co-morbidities, such as immune system disorders, tumors, etc.

• Test confirms poor response to ZOL and IL-2 stimulation.